A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative, Intermediate Risk Early Breast Cancer

Trial Profile

A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative, Intermediate Risk Early Breast Cancer

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 25 Apr 2017

At a glance

  • Drugs Ribociclib (Primary)
  • Indications Adenocarcinoma; Breast cancer
  • Focus Therapeutic Use
  • Acronyms EarLEE-2
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 19 Apr 2017 Planned End Date changed from 13 Jan 2025 to 27 Jan 2025.
    • 19 Apr 2017 Planned primary completion date changed from 13 Jan 2025 to 27 Jan 2025.
    • 19 Apr 2017 Planned initiation date changed from 25 May 2017 to 9 Jun 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top